Nasal sprays can treat congestion and other symptoms of seasonal allergies or a cold. They work by delivering a fine mist of medication into your nostrils. Since the lining of your nose is rich with ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

A pimple-like bump or sore inside the nose can sometimes be due to nasal vestibulitis or nasal folliculitis. It is a bacterial infection that can develop when hair follicles become infected ...

But hidden at your pharmacy among the potpourri of cough drops and cold remedies, you can find a low-risk treatment that actually may help: nasal irrigation devices. Several small studies suggest ...

A nasal rinse is a common practice to clear nasal passages, especially during cold, flu, and allergy seasons. It helps remove mucus, debris, and allergens that build in the nose. “A saltwater rinse is ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

Nasal spray is being recalled over microbial failure. The U.S. Food and Drug Administration shared information about the recall affecting NeilMed Pharmaceuticals’ NasoGel Spray, last week. Here ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...